Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Forecast improvement within reach

Successful HFpEF therapy for the first time

    • Cardiology
    • Interviews
    • RX
    • Studies
  • 2 minute read

Prof. Stefan Anker, MD, provides a summary overview of the key outcomes of the EMPEROR-Preserved study.

Prof. Dr. med. Stefan Anker

Berlin-Brandenburg Center for Regenerative Therapies
Charité, University Medicine Berlin (D)

 

Can you give us a summary overview of the key outcomes of the EMPEROR-Preserved study?


Prof. Anker, MD:
This is the first success that can be recorded in the therapy of HFpEF. To put it in a nutshell: We are now seeing a success that has not happened for the last 18 years – despite five different attempts. It showed a really significant difference, which is also statistically significant – in a way that leaves no doubt. The 21% risk reduction is a difference that can not only be measured, but also felt. This is because patients’ symptoms and quality of life also improve. There are two aspects to quality of life: On the one hand, the quality of life measurable by questionnaires improved. But not having to spend part of your life in the hospital also promotes this significantly.

The positive results are predominantly due to the reduction in hospital stays. How should this fact be classified?

The study – and with it all other precursor studies as well – was designed to establish combined endpoints. So all-cause or cardiovascular mortality, as well as heart failure and hospitalization rates. The latter either as the first event or as the first and repeated events. The question then becomes how many hospitalizations happen and how quickly. This is because these are no longer included in the cardiovascular mortality endpoint. Now we are currently in a pandemic in which cardiovascular mortality has actually turned out to be a little higher than expected. Approximately one-third of all primary endpoints are cardiovascular deaths. The 21% identified corresponds to the combined endpoint. Looking at the individual components, while the reduction in cardiovascular mortality was 9%, heart failure hospitalization was more than 25% for both the first and repeat events, which was highly significant. This is relevant to patients because heart failure hospitalization affects prognosis. To see effects in mortality, the study may also not have been long enough, with a follow-up of 26 months. But aside from the resources needed for a longer study, it would also be unethical to continue such a study even though it has met the combined endpoint. Patients deserve to have this option for treatment.

The interview was conducted by Leoni Burggraf

 

 

CARDIOVASC 2021; 20(3): 38

Publikation
  • CARDIOVASC
Related Topics
  • HFpEF
Previous Article
  • Idiopathic pulmonary fibrosis

Change of therapy often useful

  • Congress Reports
  • Pneumology
  • RX
  • Studies
View Post
Next Article
  • Pelargonium sidoides

Enhanced antiviral effects through upregulation of the vitamin D receptor.

  • Education
  • General Internal Medicine
  • Infectiology
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 7 min
  • Steatotic liver disease

GLP-1RA in MASH – what’s new?

    • Congress Reports
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 6 min
  • Chronic pruritus: “Tour d'horizon”

Focus on new anti-inflammatory therapeutic approaches

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 5 min
  • Multiple sclerosis

Unexpected side effects when switching from natalizumab to a biosimilar

    • Education
    • Neurology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 3 min
  • Immunotherapy

Subcutaneously or intravenously?

    • Congress Reports
    • Oncology
    • Pneumology
    • RX
    • Studies
View Post
  • 4 min
  • Work-related asthma

When the job leads to exacerbations

    • Allergology and clinical immunology
    • Education
    • General Internal Medicine
    • Pneumology
    • RX
    • Studies
View Post
  • 0 min
  • Inoperable NSCLC

Efficacy of pembrolizumab in combination with concurrent chemoradiotherapy

    • Congress Reports
    • Oncology
    • Pneumology
    • RX
    • Studies
View Post
  • 3 min
  • De-escalation strategies

De-escalation strategies – less is more

    • Congress Reports
    • Oncology
    • Pneumology
    • Prevention and health care
    • RX
View Post
  • 16 min
  • Pain and autism

Hurdles to pain treatment for autistic patients

    • CME continuing education
    • Pediatrics
    • Pharmacology and toxicology
    • Psychiatry and psychotherapy
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Hurdles to pain treatment for autistic patients
  • 2
    Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)
  • 3
    Treatment of comorbidities in older people
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Rare malignancy from a dermatological perspective

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.